ArticleFrontiers in cardiovascular medicine2021
Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction.
Article in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Neutrophil-mediated effects of S100A12 on major adverse cardiovascular events: Insights from the UK biobank.American journal of preventive cardiology · 2025Article
- Determining the biomarkers and pathogenesis of myocardial infarction combined with ankylosing spondylitis via a systems biology approach.Frontiers of medicine · 2025Article
- Association between S100A12 and risk of peripheral arterial disease in patients with dyslipidemia: a cross-sectional study.BMC cardiovascular disorders · 2025Article
- S100A12 triggers NETosis to aggravate myocardial infarction injury via the Annexin A5-calcium axis.Nature communications · 2025Article
- Single-Cell RNA Sequencing of PBMCs Identified Junction Plakoglobin (JUP) as Stratification Biomarker for Endometriosis.International journal of molecular sciences · 2024Article
- Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities.Circulation research · 2024Review
- Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- New Insights into the Role of HMGB2 in ST-Segment Elevation Myocardial Infarction.International journal of general medicine · 2023Article
- Construction of Novel Gene Signature-Based Predictive Model for the Diagnosis of Acute Myocardial Infarction by Combining Random Forest With Artificial Neural Network.Frontiers in cardiovascular medicine · 2022Article
- Inflammation and Oxidative Stress Role of S100A12 as a Potential Diagnostic and Therapeutic Biomarker in Acute Myocardial Infarction.Oxidative medicine and cellular longevity · 2022Article
- Bioinformatics analysis to identify potential biomarkers and therapeutic targets for ST-segment-elevation myocardial infarction-related ischemic stroke.Frontiers in neurology · 2022Article
- Human Plasma Transcriptome Implicates Dysregulated S100A12 Expression: A Strong, Early-Stage Prognostic Factor in ST-Segment Elevated Myocardial Infarction: Bioinformatics Analysis and Experimental Verification.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.